CYP2D6 and Gaucher disease type 1: Eliglustat is indicated for adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs) and thus should be genotyped for CYP2D6 to determine the CYP2D6 metaboliser status.